Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

Detailed price information for Oppenheimer Russell 2000 Multifactor ETF (OMFS-A) from The Globe and Mail including charting and trades.